Trials / Completed
CompletedNCT01014429
Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors
A Phase I Dose Escalation Study of NMS-1286937 Administered to Adult Patients With Advanced/Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Nerviano Medical Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of NMS-1286937, a polo-like-kinase 1 inhibitor, in patients with advanced metastatic solid tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NMS-1286937 | Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops. |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2011-10-01
- First posted
- 2009-11-17
- Last updated
- 2012-09-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01014429. Inclusion in this directory is not an endorsement.